Products for Research Use Only

Alfuzosin-d7

CAT: 0804-HY-B0192SSize: 500 µgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-B0192SSize:500 µg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Alfuzosin-d7 is the deuterium labeled Alfuzosin[1]. Alfuzosin (SL 77499-10) is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin can be used in study of benign prostatic hyperplasia (BPH) [2][3].
CAS Number
1133386-93-2
Product Name Alternative
SL 77499-d7
UNSPSC
12352005
Hazard Statement
H302
Target
Adrenergic Receptor
Type
Isotope-Labeled Compounds
Related Pathways
GPCR/G Protein; Neuronal Signaling
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Endocrinology
Solubility
10 mM in DMSO
Smiles
NC1=NC(N(C)CCCNC(C2([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])O2)=O)=NC3=C1C=C(OC)C(OC)=C3
Molecular Formula
C19H20D7N5O4
Molecular Weight
396.49
Precautions
H302
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.|[2]Martin DJ, et al. Relationship between the effects of alfuzosin on rat urethral and blood pressures and its tissue concentrations. Life Sci. 1998;63 (3) :169-76. |[3]Wilde MI, et al. Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drugs. 1993 Mar45 (3) :410-29.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported